By Josh Beckerman

AstraZeneca PLC shares were up 6% after hours to $56.53 as the company said its Tagrisso drug "demonstrated unprecedented patient benefit in the adjuvant treatment of EGFR-mutated lung cancer" in the Phase III ADAURA trial.

The company said Tagrisso "demonstrated a statistically significant and clinically meaningful improvement in disease-free survival."

AstraZeneca said the results "demonstrate for the first time in a global trial that an EGFR inhibitor can change the course of early-stage EGFR-mutated lung cancer and provide hope for a cure," and the company is "discussing these outstanding data with regulatory authorities."

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

May 28, 2020 17:58 ET (21:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca